Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

bidly with dementia and excessive day time sleepiness. We believe that ITI-002 will be uniquely effective in treating these non-motor complications that are associated with Parkinson's disease."

ABOUT ITI-002

ITI-002 is a unique, orally available, investigational drug being developed for the treatment of motor and non-motor impairments accompanying Parkinson's disease and other neurologic and neuropsychiatric disorders, including schizophrenia and Alzheimer's disease.

ITI-002 potently inhibits the PDE1 enzyme in a competitive manner with sub-nanomolar affinity for this subfamily. This compound is very selective for the PDE1 subfamily relative to other PDE subfamilies. ITI-002 has no significant off target activities at other enzymes, receptor or ion channels.

PDE Type I – PDE enzymes hydrolyze and inactivate cyclic nucleotides (cAMP and cGMP) in the brain.  Eleven classes of PDE enzymes with distinct tissue distributions, cyclic nucleotide selectivity, and regulatory factors are known.  The PDE1 family of enzymes, including PDE1A, PDE1B, and PDE1C isoforms, are calcium/calmodulin-dependent, dual-function (cAMP/cGMP) PDEs that are expressed at high levels in mammalian brain. This enzyme subfamily has little influence on basal nucleotide activity and only becomes active under stimulated conditions.  This "on demand" character distinguishes PDE1 from all other PDE family members. PDE1 is enriched in the striatal medium spiny neurons that lose dopamine input in Parkinson's disease and controls the responsiveness of striatal neurons to dopamine. Intra-Cellular Therapies has shown that orally available, small molecule inhibitors of PDE1 restore dopamine signaling in striatal neurons and potentiate the level of motor correction in Parkinson's disease.

About Parkinson's Disease - Parkinson's disease is a progressive, neurodegenerative disease. The prevalence of Parkinson's disease increases with a
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015 The International Myeloma Foundation (IMF) ... while working toward prevention and a cure – will ... Group (IMWG) Summit June 8-10 in Vienna, ... attend the 2015 Summit, which convenes on the eve ... (EHA).  The focus of the IMWG is on incorporating ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 CIRTEC ... device manufacturing services for complex Class III implantable devices ... a new UT Dallas-led initiative aimed at identifying potentially ... System institutions and moving them more efficiently from ... a long history of working with the world's largest ...
(Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
(Date:6/3/2015)... London (PRWEB) June 03, 2015 ... set a new world record by scaling CD-adapco’s ... the Blue Waters supercomputer. , STAR-CCM+ is ... many industries to stimulate innovation and lower product ... Program and Blue Waters manufacturer Cray to push ...
Breaking Biology Technology:International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 2International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 3International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 4CIRTEC Medical Systems to support new UT Dallas-led Initiative to deliver biomedical technologies from laboratory bench to bedside more efficiently 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3
... 9, 2011 PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... offer, subject to market and other conditions, $135 million aggregate ... under the Company,s shelf registration statement filed with the U.S. ... Company also expects to grant the underwriters a 13-day overallotment ...
... La., May 9, 2011 Following a rigorous ... LLC (AE) have been recommended 1st for state ... (ITRS) component of the Board of Regents Support ... their proposal to develop breakthrough technology for harvesting ...
... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 2LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 3
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... YORK July, 16, 2008 When it comes to ... us. Our immune systems respond to foreign substances with ... they,ve encountered in the past. Normally, anything previously identified as ... goes awry, triggering an allergic reaction. , ...
... active. The key to being active is to be born ... fitness has created the idea that individuals can manage their ... to engage in physical activity is itself significantly affected by ... inclination to exercise may be strongly affected by genetics. ...
... federal grant will allow Johns Hopkins researchers to purchase ... their efforts to find new ways to diagnose and ... ailments. The Institute for Computational Medicine, based ... one of the 20 High-End Instrumentation Grants for 2008 ...
Cached Biology News:Asthma and other allergies tied to absence of specialized cells 2Asthma and other allergies tied to absence of specialized cells 3Can you be born a couch potato? 2Can you be born a couch potato? 3$2 million computer will help unravel major medical ailments 2$2 million computer will help unravel major medical ailments 3
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
IEX-1 S/L (H-20)...
Biology Products: